On Thursday, the Horseracing Integrity and Safety Authority released it’s draft Prohibited Substances Technical Document, along with screening limits and detection times, for public comment.
The full document is available on HISA’s website, at this link.
According to a letter from HISA Anti-Doping and Medication Control Program committee chair Adolpho Birch, the term “prohibited substances” refers to both banned substances, which should never be administered to a covered horse, and controlled medication substances, which may be appropriate for use outside the race period.
The letter explains that the HISA act requires the Authority to rely on the International Federation of Horseracing Authorities’ baselines for urine and blood plasma screening, unless stricter standards exist. However, the letter goes on to state that the act permits deviations in those baselines if they are approved by the ADMC committee and the enforcement agency, and requests that stakeholders suggesting changes do so with supporting rationale and scientific evidence.
Substances which show a higher risk of being introduced to a horse’s system via contamination (“specified substances”) are marked on the document with an “X.”
Finally, the letter clarifies questions about substances which are not FDA-approved (ex. bromhexine), or which are only FDA-approved in species other than horses (ex. naproxen, meloxicam), or on which the IFHA does not offer screening limits (ex. methocarbamol, ranitidine); these will be controlled by laboratory limits of detection, and no guidance will be offered on their use.
The draft prohibited substances document is now open for public and stakeholder comment, which can be submitted by emailing [email protected].